Vaccine effectiveness against the B.1.617.2 in the intensive care unit

Abstract

Severe acute respiratory syndrome-coronavirus 2 and its variants are still a concern for the World. The effectiveness of the BioNTech and Sinovac vaccines against the B.1.617.2 variant, particularly in the intensive care unit, has been unclear. This study aimed to investigate the vaccine effectiveness of BioNTech and Sinovac vaccines in reducing severe disease, intubation, and mortality rates in B.1.617.2 infected patients followed in the intensive care unit. The data of 208 unvaccinated and 234 vaccinated B.1.617.2 variants were retrospectively reviewed. Severe disease status, complaints, the percent oxygen saturation in the blood at the first admission, and other clinical information during follow-up were recorded. With the BioNTech and Sinovac vaccines being the most common in the region, mortality rate, severe disease, and intubation were more frequent in the unvaccinated group. As for survival rates, 58.5 (137) of the vaccinated and 35.1 % (73) of the unvaccinated survived. In the vaccinated group, 64.3 % (27) of vaccinated with 3 Sinovac, 80 % (16) of 2 Sinovac and 1 BioNTech, and 71.7 % of 2 BioNTech survived. Vaccination with 2 doses of BioNTech and 3 doses of Sinovac reduces mortality. Furthermore, 2 doses of Sinovac and 1 dose of BioNTech are more protective.

Estimation of the effect of vaccination in critically ill COVID-19 patients, analysis using propensity score matching

“…The mortality was significantly higher in unvaccinated patients than vaccinated patients (60% vs 43.7%, p < 0.0001). Similar mortality was observed in a study from Turkey [ 7 ].…”

“…A recent study from Turkey showed BioNTech and Sinovac vaccination reduced the severity of illness, need for invasive ventilation, and mortality. The hospital mortality was 41.5% in vaccinated as against 64.9% in the unvaccinated patients [ 7 ]. The UK app-based study from London showed frailty was one of the risk factors associated with breakthrough infections in the above 60 years age group after the first dose.…”